Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Lower Incidence of Brain Metastases Observed With Early Detection Screening in Lung Cancer

June 30th 2021

Early detection of primary lung cancer using low-dose computed tomography screening was associated with a lower risk of brain metastases after PLC diagnosis vs other methods

NRG1 Fusions Confer Low PD-L1, Low TMB, and Limited Immunotherapy Responses in Lung Cancer

June 30th 2021

NRG1 fusions, which are often first detected by RNA-based sequencing, confer a more molecularly, pathologically, and clinically diverse subtype of lung cancer compared with historical hypotheses.

Targeted Therapy Paradigm Grows in NSCLC, While Overcoming Resistance Represents Next Hurdle

June 29th 2021

The field of targeted therapy for patients with non–small cell lung cancer has grown exponentially in recent years, with inhibitors for RET, MET exon 14 skipping, and KRAS G12C mutations transforming the paradigm.

Early Relapse Confers Worse Prognosis After Transplant, Calling for Novel Options in High-Risk MCL

June 23rd 2021

Peter Riedell, MD, discusses the rationale for a study in mantle cell lymphoma, the clinical implications of the findings, and unanswered questions that future research efforts should aim to answer.

Navigating Newfound Options, MRD Assessment, and Emerging Approaches in Multiple Myeloma

June 21st 2021

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

Transfusion Independence With Momelotinib Confers Benefit Regardless of Baseline Factors in Myelofibrosis

June 18th 2021

Achieving transfusion independence after 24 weeks of treatment with momelotinib is associated with clinical benefit in patients with myelofibrosis irrespective of the degree of anemia, platelet count, or transfusion status at baseline.

Quadruplets, Immune-Based Regimens Slated to Expand the Frontline Myeloma Paradigm

June 18th 2021

Daratumumab-based quadruplet regimens and cutting-edge immune-based therapies are positioned to become potential standard options in frontline multiple myeloma treatment.

Symptom Improvement Appears Similar With Momelotinib Vs Ruxolitinib in Myelofibrosis

June 17th 2021

Momelotinib can provide clinically relevant and comparable improvement in overall symptom burden and individual symptom items compared with ruxolitinib in patients with intermediate- and high-risk JAK inhibitor–naïve myelofibrosis.

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

June 15th 2021

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Axi-Cel Provides Durable Responses in Higher-Risk Follicular Lymphoma and MZL, Regardless of POD24 Status

June 11th 2021

Axicabtagene ciloleucel demonstrated significant clinical activity with durable responses in patients with relapsed/refractory indolent non-Hodgkin lymphoma who experienced disease progression within 24 months from initiation of the first anti-CD20–containing chemotherapy, which is a high-risk clinical feature.

Allo-Transplant Recommended for Eligible Patients With Myelofibrosis

June 10th 2021

Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.

Cabozantinib Exposure Not Associated With PFS, But Is Linked With Higher AEs With Cabozantinib/Nivolumab in RCC

June 9th 2021

Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.

Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant Medullary Thyroid Cancer

June 6th 2021

Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy.

Frontline Camrelizumab Plus Chemotherapy Improves Survival in Advanced Esophageal Squamous Cell Carcinoma

June 5th 2021

Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Mobocertinib Elicits Anticancer Activity in Platinum-Pretreated EGFR Exon 20 Insertion+ Advanced NSCLC

June 4th 2021

Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.

Neoadjuvant Cemiplimab Induces Tumor Necrosis in Resectable HCC

June 1st 2021

Parissa Tabrizian, MD, MSc, discusses the rationale for evaluating cemiplimab in the neoadjuvant setting for patients with resectable hepatocellular carcinoma, the results of the trial, and next steps planned to identify optimal clinical end points that correlate with survival benefit.

Real-World Data Reflect Shorter Survival With Pembrolizumab in Older NSCLC Population

May 28th 2021

Pembrolizumab alone and in combination with chemotherapy was associated with shorter overall survival compared with the data demonstrated in the registrational clinical trials in older Medicare patients with advanced non–small cell lung cancer, providing real-world insight into the prognosis of older patients with NSCLC who are treated with immunotherapy.

Single-Hit TP53 Associated With Prolonged OS and PFS Vs Multi-Hit TP53 in Ibrutinib-Treated CLL

May 27th 2021

Patients with chronic lymphocytic leukemia and single-hit TP53 mutations derived long-term responses with ibrutinib monotherapy, whereas patients with multi-hit TP53 aberrations had shortened progression-free survival.

Research Collaboration Aims to Bring TLR9 Agonist SD-101 to Patients With Pancreatic and Liver Cancer

May 27th 2021

The University of Texas MD Anderson Cancer Center and the immuno-oncology company TriSalus™ Life Sciences announced a strategic research collaboration to evaluate SD-101 in pancreatic cancer and hepatocellular carcinoma.